Product Highlight - Rexulti
16 Sep 2020
REXULTI® (Brexpiprazole) Tablet is an Atypical Antipsychotic as a “Serotonin-Dopamine Activity Modulator” (SDAM) that combines partial agonist activity at serotonin 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors (Ki: 0.1 nM to 0.5 nM).
Brexpiprazole also shows antagonist activity at noradrenergic α1B/2C receptors with affinity in the same sub-nanomolar Ki range (Ki: 0.2 nM to 0.6 nM).
Indication:
Adjunctive treatment for major depressive disorder (MDD) in adult
Treatment of schizophrenia in adult
Dosage and Administration: Schizophrenia: Starting dose: 1 mg once daily on days 1-4. Recommended dose: 2-4 mg once daily (Be titrated to 2 mg once daily on day 5 through day 7 and then to 4 mg on day 8). Maximum daily dose: 4 mg.
MDD: Starting dose: 0.5 mg or 1 mg once daily. Recommended dose: 2 mg once daily (Dosage increases should occur at weekly intervals). Maximum daily dose: 3 mg.
Reference: Prescribing Information of REXULTI
THAI OTSUKA PHARMACEUTICAL CO., LTD.
15th Floor, Unit no.1501-1502 United Center Building, 323 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand
• Tel: (+66) 2401 9560 ext. 1085
• Fax: (+66) 2401 9561
